Manish Shah, MD
Enriched profileDirector, Gastrointestinal Oncology Program, Weill Cornell Medicine; Chief, Solid Tumor Service, NewYork-Presbyterian Hospital; Bartlett Family Professor in Gastrointestinal Oncology; Professor of Medicine, Weill Cornell Medical College · Weill Cornell Medicine
Manish Shah is Director, Gastrointestinal Oncology Program, Weill Cornell Medicine; Chief, Solid Tumor Service, NewYork-Presbyterian Hospital; Bartlett Family Professor in Gastrointestinal Oncology; Professor of Medicine, Weill Cornell Medical College at Weill Cornell Medicine. OpenAlex indexes 662 publications with 34,069 citations (h-index 83); ClinicalTrials.gov lists 21 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 27 Aug 2026
Manish A. Shah, MD, is Director, Gastrointestinal Oncology Program, Weill Cornell Medicine. The public record shows 662 publications with 34,069 citations (h-index 83), centered on Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 32 companies, 8 NIH-funded awards (2006–2026).
- Most recent indexed publication: 2026 · Science advances
- Top research focus: Gastric Cancer Management and Outcomes
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 32 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 35 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 232.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- Assessing CSF Flow Dynamics in Pediatric Hemorrhagic Hydrocephalus
Sponsor: Eva Sevick
- Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Sponsor: Weill Medical College of Cornell University
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Sponsor: Weill Medical College of Cornell University
Industry payments
Updated 27 Aug 2026
32 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202513 payments$17,581openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year20253 payments$10,820openpaymentsdata.cms.gov ↗
- AstraZeneca UK LimitedProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
80.4%Platinum-based Drug70.7%Oxaliplatin100%Part B, office-administered≥22 patientsNucleoside Metabolic Inhibitor7.2%Fluorouracil62%Gemcitabine hydrochloride39%Part B, office-administered≥32 patientsMetabolism & gastrointestinal
14.1%Anticholinergic7.6%Atropine sulfate100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist6.5%Palonosetron hcl100%Part B, office-administered≥37 patientsSensory organs
3%Corticosteroid3%Dexamethasone sodium phosphate100%Part B, office-administered≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
8 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:
- Pediatric Dose Optimization for Seizures in EMS (PediDOSE)
Stanford University
FY2026$2,717,413U01NS114042 - Geriatrics Emergency care Applied Research Network 2.1 - AdvanCing and Expanding Dementia care (GEAR 2.1 - ACED)
New York University School of Medicine
FY2026$748,222R33AG069822 - Assessing CSF flow dynamics in pediatric hemorrhagic hydrocephalus
University of Texas Hlth Sci Ctr Houston
FY2026$564,926R01NS126437
Congress activity
Updated 27 Aug 2026
174 congress contributions (2004–2026) across AACR, ASCO, ASH, ENDO, ESMO per OpenAlex. The most recent:
- Liver transplantation (LT) in liver limited metastatic colorectal cancer (CRC): Insights and opportunities.
ASCO Annual Meeting
ASCO2026Co-author - Nationwide oncologist survey on biomarker integration and evidence-based gastric/GEJ cancer care: Practice patterns and barriers.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update.
Journal of clinical oncology
Guideline2026 - Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort.
Communications medicine
Article2026 - Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients.
Cancer research communications
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/manish-shah-md-9339551b
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Doximity
doximity.com/pub/manish-shah-md-d8c75aa7
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/manish-shah-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Spotify
open.spotify.com/show/6MQnPwZIXJHrCVBBxhTt37
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗ - YouTube
youtube.com/playlist
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
- Board Certified
Internal Medicine, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗ - Board Certified
Medical Oncology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
Editorial & leadership roles
journal and society appointments- Expert Panel Co-Chair
ASCO Guideline: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Guideline Co-Chair
ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline and Rapid Recommendation Update
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopubs.org ↗ - Gastrointestinal Disease Section Editor
journal Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →meyercancer.weill.cornell.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
Media & interviews
press, podcasts and appearances- Host
CancerCast podcast (Weill Cornell Medicine) -- research breakthroughs, therapies, and patient survivorship stories
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jedd Wolchok, MD
Weill Cornell Medicine
Ronald Crystal, MD
Weill Cornell Medicine
Robert Harrington, MD
Weill Cornell Medicine
Giuseppe Giaccone, MD, PhD
Weill Cornell Medicine